内分泌指南

订阅

MedSci主页 / 所有栏目 / 内分泌指南

2021 国际多学科共识声明：射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病

2021-12-23 美国头颈学会 Head Neck

射频消融甲状腺疾病

超声引导下消融治疗甲状腺良恶性疾病越来越受关注，本文主要针对射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病提供共识指导。内容涉及术前评估、技术、术后管理、疗效和潜在并发症等方面。

中文标题：

2021 国际多学科共识声明：射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病

英文标题：

Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement

发布机构：

美国头颈学会

发布日期：

2021-12-23

简要介绍：

超声引导下消融治疗甲状腺良恶性疾病越来越受关注，本文主要针对射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病提供共识指导。内容涉及术前评估、技术、术后管理、疗效和潜在并发症等方面。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 国际多学科共识声明：射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病 (1).pdf)] GetToolGuiderByIdResponse(projectId=1, id=b5f2e1c002301320, title=2021 国际多学科共识声明：射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病, enTitle=Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement, guiderFrom=Head Neck, authorId=0, author=, summary=超声引导下消融治疗甲状腺良恶性疾病越来越受关注，本文主要针对射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病提供共识指导。内容涉及术前评估、技术、术后管理、疗效和潜在并发症等方面。, cover=https://img.medsci.cn/20211224/1640354191097_1608702.jpg, journalId=0, articlesId=null, associationId=1307, associationName=美国头颈学会, associationIntro=, copyright=0, guiderPublishedTime=Thu Dec 23 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">超声引导下消融治疗甲状腺良恶性疾病越来越受关注，本文主要针对射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病提供共识指导。内容涉及术前评估、技术、术后管理、疗效和潜在并发症等方面。</span></p>, tagList=[TagDto(tagId=666, tagName=射频消融), TagDto(tagId=3313, tagName=甲状腺疾病)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌, tenant=100), CategoryDto(categoryId=40, categoryName=影像放射, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=666, guiderKeyword=射频消融, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=10, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3135, appHits=158, showAppHits=0, pcHits=769, showPcHits=2977, likes=0, shares=28, comments=10, approvalStatus=1, publishedTime=Fri Dec 24 21:50:41 CST 2021, publishedTimeString=2021-12-23, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Fri Dec 24 22:02:34 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 22:19:06 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 国际多学科共识声明：射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病 (1).pdf)])
2021 国际多学科共识声明：射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病 (1).pdf
下载请点击：
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1230128, encodeId=15c31230128e4, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03f58224280, createdName=ms1000001349037147, createdTime=Sat Jul 02 13:17:28 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084504, encodeId=0fb3108450477, content=👍👍赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210816/d6f733f1d88b4a3eacb17c6ae60fee1e/60bac44ce944447294ee076bcbedc201.jpg, createdBy=d4935293116, createdName=李娜3724, createdTime=Sun Dec 26 22:36:58 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206134, encodeId=f27b1206134dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e24e5619067, createdName=ms5000000063737375, createdTime=Sat Mar 26 16:30:20 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185446, encodeId=11e31185446c8, content=👌, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:36:41 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179593, encodeId=b3cf11e9593cb, content=实用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:47 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
    2022-07-02 ms1000001349037147

    赞赞赞

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1230128, encodeId=15c31230128e4, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03f58224280, createdName=ms1000001349037147, createdTime=Sat Jul 02 13:17:28 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084504, encodeId=0fb3108450477, content=👍👍赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210816/d6f733f1d88b4a3eacb17c6ae60fee1e/60bac44ce944447294ee076bcbedc201.jpg, createdBy=d4935293116, createdName=李娜3724, createdTime=Sun Dec 26 22:36:58 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206134, encodeId=f27b1206134dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e24e5619067, createdName=ms5000000063737375, createdTime=Sat Mar 26 16:30:20 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185446, encodeId=11e31185446c8, content=👌, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:36:41 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179593, encodeId=b3cf11e9593cb, content=实用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:47 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
    2021-12-26 李娜3724

    👍👍赞

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1230128, encodeId=15c31230128e4, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03f58224280, createdName=ms1000001349037147, createdTime=Sat Jul 02 13:17:28 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084504, encodeId=0fb3108450477, content=👍👍赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210816/d6f733f1d88b4a3eacb17c6ae60fee1e/60bac44ce944447294ee076bcbedc201.jpg, createdBy=d4935293116, createdName=李娜3724, createdTime=Sun Dec 26 22:36:58 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206134, encodeId=f27b1206134dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e24e5619067, createdName=ms5000000063737375, createdTime=Sat Mar 26 16:30:20 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185446, encodeId=11e31185446c8, content=👌, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:36:41 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179593, encodeId=b3cf11e9593cb, content=实用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:47 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
    2022-03-26 ms5000000063737375

    好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1230128, encodeId=15c31230128e4, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03f58224280, createdName=ms1000001349037147, createdTime=Sat Jul 02 13:17:28 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084504, encodeId=0fb3108450477, content=👍👍赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210816/d6f733f1d88b4a3eacb17c6ae60fee1e/60bac44ce944447294ee076bcbedc201.jpg, createdBy=d4935293116, createdName=李娜3724, createdTime=Sun Dec 26 22:36:58 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206134, encodeId=f27b1206134dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e24e5619067, createdName=ms5000000063737375, createdTime=Sat Mar 26 16:30:20 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185446, encodeId=11e31185446c8, content=👌, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:36:41 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179593, encodeId=b3cf11e9593cb, content=实用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:47 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
    2022-01-18 ms6000000807686529

    👌

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1230128, encodeId=15c31230128e4, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03f58224280, createdName=ms1000001349037147, createdTime=Sat Jul 02 13:17:28 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084504, encodeId=0fb3108450477, content=👍👍赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210816/d6f733f1d88b4a3eacb17c6ae60fee1e/60bac44ce944447294ee076bcbedc201.jpg, createdBy=d4935293116, createdName=李娜3724, createdTime=Sun Dec 26 22:36:58 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206134, encodeId=f27b1206134dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e24e5619067, createdName=ms5000000063737375, createdTime=Sat Mar 26 16:30:20 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185446, encodeId=11e31185446c8, content=👌, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:36:41 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179593, encodeId=b3cf11e9593cb, content=实用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:47 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
    2022-01-01 一己怀

    实用

    0

相关指南

影像引导射频消融治疗肺部肿瘤专家共识-2018年版（英文版）

中国肿瘤科相关专家小组（统称） · 2018-07-20

拓展阅读

影像引导射频消融治疗肺部肿瘤专家共识-2018年版（英文版）

中国肿瘤科相关专家小组（统称） · 2018-07-20

2020欧洲甲状腺学会《影像引导下良性甲状腺结节热消融治疗临床实践指南》解读

南京中医药大学附属中西医结合医院内分泌科 · 2022-01-20

射频或微波消融治疗乳腺纤维腺瘤中国专家共识（2022版）

中华医学会外科学分会乳腺外科学组 · 2022-11-01

2023 NICE 介入手术指南：射频消融作为球囊后凸成形术或经皮椎体成形术的辅助手段，用于缓解疼痛性脊柱转移瘤 [IPG759]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-04-05